Seizures Associated With Cdkl5 Deficiency Disorders — Patent Landscape
1
Approved drugs
11
Active US patents
73/100
Avg vulnerability
—
Annual revenue covered
Originators in Seizures Associated With Cdkl5 Deficiency Disorders
Cliff calendar — next 15 years
6
26
1
31
2
37
Approved drugs ranked by patent estate
| Drug | Originator | Active patents | Avg vuln | Revenue | First cliff |
|---|---|---|---|---|---|
|
Ztalmy
GANAXOLONE
|
Marinus | 11 | 73 | — | 2026-11-28 |
Most attackable patents
| Patent | Drug | Type | Vuln | Expiry |
|---|---|---|---|---|
| 8618087 | Ztalmy | method of use | 88 | 2026-11-28 |
| 9056116 | Ztalmy | method of use | 88 | 2026-11-28 |
| 12144801 | Ztalmy | method of use | 75 | 2037-08-10 |
| 12268696 | Ztalmy | method of use | 75 | 2042-09-30 |
| 12115169 | Ztalmy | method of use | 75 | 2042-09-30 |
| 10603308 | Ztalmy | method of use | 70 | 2037-08-10 |
| 9029355 | Ztalmy | formulation | 68 | 2026-11-28 |
| 7858609 | Ztalmy | formulation | 68 | 2026-11-28 |
| 8022054 | Ztalmy | formulation | 68 | 2026-11-28 |
| 8367651 | Ztalmy | formulation | 68 | 2026-11-28 |
Strongest defences
| Patent | Drug | Type | Vuln | Expiry |
|---|---|---|---|---|
| 8318714 | Ztalmy | formulation | 56 | 2031-11-28 |
| 8367651 | Ztalmy | formulation | 68 | 2026-11-28 |
| 7858609 | Ztalmy | formulation | 68 | 2026-11-28 |
| 8022054 | Ztalmy | formulation | 68 | 2026-11-28 |
| 9029355 | Ztalmy | formulation | 68 | 2026-11-28 |
| 10603308 | Ztalmy | method of use | 70 | 2037-08-10 |
| 12115169 | Ztalmy | method of use | 75 | 2042-09-30 |
| 12268696 | Ztalmy | method of use | 75 | 2042-09-30 |
| 12144801 | Ztalmy | method of use | 75 | 2037-08-10 |
| 8618087 | Ztalmy | method of use | 88 | 2026-11-28 |
Related
- Seizures Associated With Cdkl5 Deficiency Disorders — full disease profile
- AI Patent Landscape Report — type "seizures associated with cdkl5 deficiency disorders" for an AI exec memo
- Company Patent Rankings
- Biosimilar Opportunity Scanner